SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Organovo Holdings, Inc. – ‘10-Q’ for 6/30/15 – ‘R10’

On:  Monday, 8/10/15, at 4:05pm ET   ·   For:  6/30/15   ·   Accession #:  1564590-15-6825   ·   File #:  1-35996

Previous ‘10-Q’:  ‘10-Q’ on 2/6/15 for 12/31/14   ·   Next:  ‘10-Q’ on 11/9/15 for 9/30/15   ·   Latest:  ‘10-Q’ on 2/8/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/10/15  Organovo Holdings, Inc.           10-Q        6/30/15   46:3.9M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    299K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     25K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
29: R1          Document and Entity Information                     HTML     38K 
22: R2          Condensed Consolidated Balance Sheets               HTML     94K 
27: R3          Condensed Consolidated Balance Sheets               HTML     28K 
                (Parenthetical)                                                  
31: R4          Unaudited Condensed Consolidated Statements of      HTML     55K 
                Operations                                                       
42: R5          Unaudited Condensed Consolidated Statements of      HTML     89K 
                Cash Flows                                                       
23: R6          Unaudited Condensed Consolidated Statements of      HTML     21K 
                Cash Flows (Parenthetical)                                       
26: R7          Description of Business and Summary of Significant  HTML    114K 
                Accounting Policies                                              
20: R8          Derivative Liability                                HTML     66K 
15: R9          Stockholders' Equity                                HTML    152K 
43: R10         Commitments and Contingencies                       HTML     52K 
33: R11         Concentrations                                      HTML     23K 
32: R12         Recent Accounting Pronouncements                    HTML     26K 
37: R13         Subsequent Events                                   HTML     19K 
38: R14         Description of Business and Summary of Significant  HTML    184K 
                Accounting Policies (Policies)                                   
36: R15         Description of Business and Summary of Significant  HTML     76K 
                Accounting Policies (Tables)                                     
39: R16         Derivative Liability (Tables)                       HTML     60K 
28: R17         Stockholders' Equity (Tables)                       HTML    136K 
30: R18         Commitments and Contingencies (Tables)              HTML     34K 
35: R19         Description of Business and Summary of Significant  HTML     82K 
                Accounting Policies - Additional Information                     
                (Detail)                                                         
46: R20         Description of Business and Summary of Significant  HTML     31K 
                Accounting Policies - Estimated Fair Values of                   
                Liabilities Measured on Recurring Basis (Detail)                 
40: R21         Description of Business and Summary of Significant  HTML     32K 
                Accounting Policies - Activity for Liabilities                   
                Measured at Estimated Fair Value Using                           
                Unobservable Inputs (Detail)                                     
24: R22         Derivative Liability - Additional Information       HTML     36K 
                (Detail)                                                         
34: R23         Derivative Liability - Assumptions Used to Value    HTML     33K 
                Derivative Liabilities at Closing Dates of Private               
                Placements (Detail)                                              
25: R24         Stockholders' Equity - Additional Information       HTML    145K 
                (Detail)                                                         
13: R25         Stockholders' Equity - Summary of Company's         HTML     29K 
                Restricted Stock Award Activity (Detail)                         
41: R26         Stockholders' Equity - Additional Information 1     HTML     54K 
                (Detail)                                                         
44: R27         Stockholders' Equity - Summary of Stock Option      HTML     52K 
                Activity (Detail)                                                
17: R28         Stockholders' Equity - Fair Value of Employee       HTML     32K 
                Stock Options (Detail)                                           
16: R29         Stockholders' Equity - Additional Information 2     HTML     78K 
                (Detail)                                                         
18: R30         Stockholders' Equity - Summary of Warrant Activity  HTML     44K 
                (Detail)                                                         
19: R31         Stockholders' Equity - Common Stock Reserved for    HTML     27K 
                Future Issuance (Detail)                                         
21: R32         Commitments and Contingencies - Additional          HTML     49K 
                Information (Detail)                                             
12: R33         Commitments and Contingencies - Future Minimum      HTML     38K 
                Rental Payments Required under Operating Leases                  
                that have Initial or Remaining Non-Cancelable                    
                Lease Terms in Excess of One Year (Detail)                       
45: XML         IDEA XML File -- Filing Summary                      XML     78K 
11: EXCEL       IDEA Workbook of Financial Reports                  XLSX     56K 
 5: EX-101.INS  XBRL Instance -- onvo-20150630                       XML   1.01M 
 7: EX-101.CAL  XBRL Calculations -- onvo-20150630_cal               XML     90K 
 8: EX-101.DEF  XBRL Definitions -- onvo-20150630_def                XML    303K 
 9: EX-101.LAB  XBRL Labels -- onvo-20150630_lab                     XML    742K 
10: EX-101.PRE  XBRL Presentations -- onvo-20150630_pre              XML    570K 
 6: EX-101.SCH  XBRL Schema -- onvo-20150630                         XSD    102K 
14: ZIP         XBRL Zipped Folder -- 0001564590-15-006825-xbrl      Zip     99K 


‘R10’   —   Commitments and Contingencies


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.2.0.727
Commitments and Contingencies
3 Months Ended
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 4. Commitments and Contingencies

Operating leases

The Company leases office and laboratory space under a non-cancelable operating lease which was entered into in February 2012 and amended in December 2013 and March 2015, and a non-cancelable operating lease entered into on January 9, 2015, with the future minimum lease payments from the leases included below. The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $481,000 to date, have been capitalized as fixed assets and included in deferred rent.

Rent expense was approximately $277,000 and $235,000 for the three months ended June 30, 2015 and 2014, respectively.

On February 27, 2012, the Company entered into a facilities lease at 6275 Nancy Ridge Drive (the “Original Lease”), San Diego, CA 92121, with occupancy as of July 15, 2012. The base rent under the lease was approximately $38,800 per month with 3% annual escalators. The lease term was 48 months with an option for the Company to extend the lease at the end of the lease term.

On December 5, 2013, the Company entered into a First Amendment (the “Amendment”) to the Original Lease, together with the Amendment, (the “Amended Lease”). Pursuant to the Amendment, the Company expanded the size of its facility by approximately 15,268 square feet (the “Expansion Premises”) from approximately 15,539 square feet (the “Original Premises”) for a total of approximately 30,807 square feet. The Amended Lease provides for base rent (i) on the Original Premises to continue at approximately $38,800 per month, with annual escalators, until August 1, 2016, at which point the base rent shall be payable at the same rate per rentable square foot as the Expansion Premises and (ii) on the Expansion Premises of approximately $38,934 per month, with 3% annual escalators, not to commence until two months after the earlier of (A) the date that the landlord delivers possession of the Expansion Premises to the Company with the work in the Expansion Lab Premises (as defined in the Amendment) substantially complete and (B) the date the landlord could have delivered the Expansion Premises with the work in the Expansion Lab Premises (as defined in the Amendment) substantially complete but for certain delays of the Company. Additionally, the Company has a right of first refusal on adjacent additional premises of approximately 14,500 square feet. The term of the Amended Lease expires on the seven-year anniversary of the earlier of (A) the date that the landlord delivers possession of the Expansion Premises to the Company and (B) the date the landlord could have delivered the Expansion Premises but for certain delays of the Company (the “Expansion Premises Commencement Date”). The Expansion Premises Commencement Date was September 1, 2014. The Company also has the option to terminate the Amended Lease on the 5-year anniversary of the Expansion Premises Commencement Date. The Expansion Premises contains office, laboratory, and clean room areas.

On March 12, 2015, the Company entered into a Second Amendment to the Original Lease (the “Second Amendment), to adjust the square footage covered by Amended Lease and an additional portion of the building containing approximately 335 rentable square feet (“Second Expansion Premises”). This square footage adjustment was the result of the re-measurement of each suite and the building overall. The net adjustment to overall leased space was an increase of 88 square feet with a corresponding increase in monthly rental payments at the same rate per square foot as the Expansion Premises.

On January 9, 2015, the Company entered into an agreement to lease a second facility consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, CA 92121. The term of the lease is 36 months, beginning on February 1, 2015 and ending on January 31, 2018, with monthly rental payments of approximately $12,000 commencing on April 1, 2015. In addition, there are annual rent escalations of 3.0% on each 12-month anniversary of the lease commencement date.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of June 30, 2015, are as follows (in thousands):

 

Fiscal year ended March 31, 2016

 

$

861

 

Fiscal year ended March 31, 2017

 

 

1,157

 

Fiscal year ended March 31, 2018

 

 

1,145

 

Fiscal year ended March 31, 2019

 

 

1,041

 

Fiscal year ended March 31, 2020

 

 

1,072

 

Thereafter

 

 

1,571

 

Total

 

$

6,847

 

 

 

Legal Matters

In addition to commitments and obligations in the ordinary course of business, the Company is subject to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.

The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

Spencer Trask Matter. In June 2013, the Company filed a declaratory relief action against Spencer Trask Ventures (“STV”) in the Supreme Court of New York (case #652305/2013) following claims by STV that it was entitled to additional compensation arising from a warrant tender offer the Company completed in December 2012. The Company is seeking a declaration that a Warrant Solicitation Agency Agreement (the “WSAA”) between the parties is a valid and enforceable agreement; the Company believes that under the terms of this agreement and the Placement Agent Agreement (the “PAA”) it entered into with STV in connection with the private placement financings the Company completed in February and March 2012, STV is not entitled to the additional compensation it is seeking.

Also in June, 2013, STV initiated an arbitration in which it is alleging (1) breach of contract, and (2) breach of confidentiality obligations under the terms of the PAA. STV is seeking compensation (including a cash fee and warrants to purchase common stock) as a result of the Company’s warrant tender offer in December 2012 and its warrant redemption in 2013, and damages for breach of confidentiality provisions in relation to the contacting of warrant holders who participated in the warrant tender offer. The Company believes there was no breach of confidentiality, as the Company’s tender offer was made to warrant holders of record relating to warrants already owned by them and whose identity was public information via a Registration Statement on Form S-1 the Company was required to file to register the resale of the shares underlying their warrants.

In January 2014, the Supreme Court of New York stayed the New York litigation, finding that the arbitrator should determine in the first instance which disputes between the Company and STV should proceed in the Arbitration and which disputes between the Company and STV should proceed in the New York Court. The parties are proceeding in the Arbitration and the Company has reserved its right to file a summary disposition motion with regard to the proper venue for its claims under the WSAA. The date for the Arbitration (previously scheduled for July, 2015) has been taken off the calendar but may be rescheduled for the fall of 2015. The Company believes that the assertions made against it by STV are without merit and the Company intends to continue to vigorously defend against the claims made by STV.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
3/31/2010-K,  10-K/A,  8-K,  CORRESP,  UPLOAD
3/31/1910-K
3/31/1810-K
1/31/18
3/31/1710-K,  5
8/1/16
3/31/1610-K,  5
Filed on:8/10/158-K
For Period end:6/30/15
4/1/158-K
3/12/154
2/1/15
1/9/15
9/1/14
6/30/1410-Q
12/5/138-K
7/15/12
2/27/12
 List all Filings 
Top
Filing Submission 0001564590-15-006825   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 2:06:21.2am ET